an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California. Cellectis S.A., a clinical stage biotechnological company, ...

Hidradenitis suppurativa (HS) is an immune disease that affects up to 4% of the global population and causes painful, recurring skin lesions and inflammation, primarily in the folds of the skin. It ...

Shahid Mukhtar and his team -- Bharat Mishra, Nilesh Kumar and graduate student YiFei Gou -- used single-cell sequencing techniques to pinpoint CD2 as a key immune receptor with elevated expression on ...

To develop the next generation of in vivo T cell therapy, Novartis will leverage Vyriad's active targeting lentiviral vector ...

THERE’S a long list of health issues linked to COVID-19, from flu-like symptoms to serious heart problems. But now a new ...

ANKET ® ( A ntibody-based NK cell E ngager T herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of ...

Researchers from Naya Biosciences Inc. and collaborators presented preclinical data on NY-303, a natural killer (NK) cell engager bispecific antibody targeting both GPC3 and NKp46. NKp46 is a cell ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

In a breakthrough discovery, scientists found that the same cells activted by severe Covid could be induced with a drug to fight multiple kinds of cancer ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and ...

T cell-based immunotherapies including immune checkpoint blockade and chimeric antigen receptor T cells can induce durable responses in patients with cancer. However, clinical efficacy is limited due ...